A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects

Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.

Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.

Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.

Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.

Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.

Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.